临床试验/NCT02023892

NCT02023892Unknown4 期

The Effect of Single Dose of Atorvastatin on Change of Circulating Endothelial Microparticles

Sun Yat-sen University0 个研究点目标入组 30 人开始时间: 2014年6月最近更新: 2014年5月15日

适应症

干预措施

试验速览

阶段: 4 期
发起方
入组人数: 30
主要终点: change of circulating endothelial microparticles

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Healthy subjects take single dose of 80mg atorvastatin, then measured their circulating endothelial microparticles and flow-mediated vasodilation in the brachial artery by ultrasound at different time points.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Prevention
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 30 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•healthy youth

排除标准

•acute pathologies
•familial history of cardiovascular disease
•smoking or drinking alcohol

研究组 & 干预措施

placebo

Placebo Comparator

placebo 20mg tablet, single dose of 80mg by mouth

干预措施: placebo (Drug)

atorvastatin

Experimental

atorvastatin 20mg tablet, single dose of 80mg by mouth

干预措施: atorvastatin (Drug)

结局指标

主要结局

change of circulating endothelial microparticles

时间窗: from 1h to 24h after taking atorvastatin

次要结局

未报告次要终点

研究者

发起方

Sun Yat-sen University

申办方类型

Other

责任方

Principal Investigator

主要研究者

Yi-jun Huang, PhD

Department of Pharmacology, Zhongshan School of Medicine

Sun Yat-sen University

相似试验

已完成

不适用

Atorvastatin and endothelial function in systemic lupus erythematosus (SLE) patientsSystemic lupus erythematosus (SLE)Musculoskeletal DiseasesSystemic lupus erythematosus

ISRCTN19073445State of São Paulo Research Foundation (FAPESP) (Brazil)88

已完成

4 期

Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk PatientsHMG-CoA Reductase Inhibitor ToxicityOxidative StressEndothelial DysfunctionAtherosclerosisCoronary Artery Disease

NCT01013103Hippocration General Hospital72

招募中

不适用

A clinical trial to find out the effect of Atorvastatin on dilatation of forearm blood vessel,in patients with Systemic Sclerosis.

CTRI/2020/07/026894Intra Mural Research Fund

已完成

1 期

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell DiseaseSickle Cell Disease

NCT00072826National Institutes of Health Clinical Center (CC)44

已完成

2 期

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell DiseaseSickle Cell NephropathySickle Cell Disease

NCT01732718University of North Carolina, Chapel Hill13